Iwaguchi T
Tokyo Research Institute, Seikagaku Corporation.
Gan To Kagaku Ryoho. 1993 Jan;20(1):1-9.
Angiogenesis (formation of new blood vessels) is essential in embryonal development, female reproduction and wound repair. Under these physiological conditions, angiogenesis is highly regulated by the endogenous angiogenic factor and its inhibitor. However, angiogenic diseases such as rheumatoid arthritis, diabetic retinopathy, solid tumor, hemangioma and psoriasis are driven by persistent unregulated angiogenesis. The angiogenic process consists of such multi-steps as degradation of basement membrane, cell migration and proliferation, and tube formation following activation of vascular endothelial cells by stimulators appearing at the pathological site. Thus, for modulating the pathological conditions, it is most important to elucidate the angiogenic mechanism at the molecular level. It is not sufficiently clear yet as compared with the blood coagulation and hematopoietic systems. On the other hand, there have been advances in the study of new anticancer metastatic agents as a target of activated endothelial cells and they have been found to have promising substances. In this study, the angiogenic factor, its inhibitor, and then the anticancer effect of the angiogenic inhibitor, have been investigated from the standpoint of cancer therapy.
血管生成（新血管的形成）在胚胎发育、女性生殖和伤口修复过程中至关重要。在这些生理条件下，血管生成受到内源性血管生成因子及其抑制剂的高度调控。然而，诸如类风湿性关节炎、糖尿病视网膜病变、实体瘤、血管瘤和牛皮癣等血管生成性疾病是由持续不受调控的血管生成所驱动的。血管生成过程包括多个步骤，如基底膜降解、细胞迁移和增殖，以及在病理部位出现的刺激物激活血管内皮细胞后形成管腔。因此，为了调节病理状况，在分子水平阐明血管生成机制最为重要。与血液凝固和造血系统相比，目前尚不够清晰。另一方面，作为激活内皮细胞的靶点，新型抗癌转移药物的研究取得了进展，并且发现了一些有前景的物质。在本研究中，从癌症治疗的角度对血管生成因子、其抑制剂以及血管生成抑制剂的抗癌作用进行了研究。
